125 related articles for article (PubMed ID: 38346928)
1. Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
Kamei M; Matsuo K; Yoshida Y; Shimada K; Otsuki M; Fujimoto N; Ishibashi M; Quan YS; Kamiyama F; Hara Y; Takamura S; Nakayama T
Int J Cancer; 2024 Jun; 154(12):2176-2188. PubMed ID: 38346928
[TBL] [Abstract][Full Text] [Related]
2. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
Front Immunol; 2018; 9():2775. PubMed ID: 30542351
[TBL] [Abstract][Full Text] [Related]
3. Transcutaneous immunization with a highly active form of XCL1 as a vaccine adjuvant using a hydrophilic gel patch elicits long-term CD8
Kamei M; Matsuo K; Imanishi H; Hara Y; Quen YS; Kamiyama F; Oiso N; Kawada A; Okada N; Nakayama T
J Pharmacol Sci; 2020 Jul; 143(3):182-187. PubMed ID: 32386904
[TBL] [Abstract][Full Text] [Related]
4. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
5.
Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
[TBL] [Abstract][Full Text] [Related]
7. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8
Gardner A; de Mingo Pulido Á; Hänggi K; Bazargan S; Onimus A; Kasprzak A; Conejo-Garcia JR; Rejniak KA; Ruffell B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34987021
[TBL] [Abstract][Full Text] [Related]
8. Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.
Le Gall C; Cammarata A; de Haas L; Ramos-Tomillero I; Cuenca-Escalona J; Schouren K; Wijfjes Z; Becker AMD; Bödder J; Dölen Y; de Vries IJM; Figdor CG; Flórez-Grau G; Verdoes M
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35428705
[TBL] [Abstract][Full Text] [Related]
9. [In Vivo Antigen Delivery to Dendritic Cells-A Novel Peptide Vaccine for Cancer Therapy].
Mizumoto Y; Katsuda M; Miyazawa M; Kitahata Y; Miyamoto A; Nakamori M; Ojima T; Matsuda K; Hemmi H; Tamada K; Kaisho T; Yamaue H
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1469-1471. PubMed ID: 30382048
[TBL] [Abstract][Full Text] [Related]
10. The invariant natural killer T cell-mediated chemokine X-C motif chemokine ligand 1-X-C motif chemokine receptor 1 axis promotes allergic airway hyperresponsiveness by recruiting CD103
Woo YD; Koh J; Kang HR; Kim HY; Chung DH
J Allergy Clin Immunol; 2018 Dec; 142(6):1781-1792.e12. PubMed ID: 29474842
[TBL] [Abstract][Full Text] [Related]
11. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
12. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
13. Conservation of a chemokine system, XCR1 and its ligand, XCL1, between human and mice.
Yamazaki C; Miyamoto R; Hoshino K; Fukuda Y; Sasaki I; Saito M; Ishiguchi H; Yano T; Sugiyama T; Hemmi H; Tanaka T; Hamada E; Hirashima T; Amakawa R; Fukuhara S; Nomura S; Ito T; Kaisho T
Biochem Biophys Res Commun; 2010 Jul; 397(4):756-61. PubMed ID: 20541533
[TBL] [Abstract][Full Text] [Related]
14. Gel-mediated recruitment of conventional type 1 dendritic cells potentiates the therapeutic effects of radiotherapy.
Wu Y; Li Q; Yan Y; Hao Y; Wang C; Liu B; Zhu Y; Liu Z; Feng L
Biomaterials; 2024 Mar; 305():122470. PubMed ID: 38228027
[TBL] [Abstract][Full Text] [Related]
15. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
16. NF-κB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity.
Ghislat G; Cheema AS; Baudoin E; Verthuy C; Ballester PJ; Crozat K; Attaf N; Dong C; Milpied P; Malissen B; Auphan-Anezin N; Manh TPV; Dalod M; Lawrence T
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34244313
[TBL] [Abstract][Full Text] [Related]
17. XCL1 and XCR1 in the immune system.
Lei Y; Takahama Y
Microbes Infect; 2012 Mar; 14(3):262-7. PubMed ID: 22100876
[TBL] [Abstract][Full Text] [Related]
18. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.
Böttcher JP; Bonavita E; Chakravarty P; Blees H; Cabeza-Cabrerizo M; Sammicheli S; Rogers NC; Sahai E; Zelenay S; Reis e Sousa C
Cell; 2018 Feb; 172(5):1022-1037.e14. PubMed ID: 29429633
[TBL] [Abstract][Full Text] [Related]
19. Structure-Function Relationship of XCL1 Used for
Kroczek AL; Hartung E; Gurka S; Becker M; Reeg N; Mages HW; Voigt S; Freund C; Kroczek RA
Front Immunol; 2018; 9():2806. PubMed ID: 30619244
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
Goding SR; Yu S; Bailey LM; Lotze MT; Basse PH
Clin Immunol; 2017 Apr; 177():76-86. PubMed ID: 27377534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
